I also went back and re-read the phase II results after GRAS decision.
Re-reading the report, I also was reasonably impressed - the phase II was a tough test... effective dosage looks easily manageable within a food product.
One question I would have is how much it costs to produce and could be supplied at. This is probably more critical in a food application than in a pharmaceutical one. After that, it may be a matter of time to market, given the requirement for shelf-life testing.
- Forums
- ASX - By Stock
- CZD
- aod9604 - efficacy and marketing
aod9604 - efficacy and marketing, page-3
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CZD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online